Clinical benefit with ripretinib as ≥ 4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study Meeting Abstract
| Authors: | Bauer, S.; Heinrich, M.; George, S.; Zalcberg, J. R.; Gelderblom, H.; Schöffski, P.; Serrano, C.; Jones, R. L.; Attia, S.; D'Amato, G.; Chi, P.; Reichardt, P.; Meade, J. N.; Reichert, V.; Shi, K.; Ruiz-Soto, R.; von Mehren, M.; Blay, J. Y. |
| Abstract Title: | Clinical benefit with ripretinib as ≥ 4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study |
| Meeting Title: | Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie (Hybrid-Kongress) |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 44 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2021 Oct 01-04 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2021-09-01 |
| Start Page: | 11 |
| Language: | English |
| ACCESSION: | WOS:000760622600023 |
| PROVIDER: | wos |
| DOI: | 10.1159/000518417 |
| Notes: | Meeting Abstract: V711 -- Meeting was also presented virtually -- "Joint Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology (Hybrid Congress)" -- Source: Wos |
